These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 16489036

  • 1. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
    Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J.
    Cancer Res; 2006 Feb 15; 66(4):2314-9. PubMed ID: 16489036
    [Abstract] [Full Text] [Related]

  • 2. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H, Saeki Y, Chiocca EA.
    Cancer Res; 2005 Dec 15; 65(24):11255-8. PubMed ID: 16357128
    [Abstract] [Full Text] [Related]

  • 3. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
    Wakimoto H, Johnson PR, Knipe DM, Chiocca EA.
    Gene Ther; 2003 Jun 15; 10(11):983-90. PubMed ID: 12756419
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2777-88. PubMed ID: 19351762
    [Abstract] [Full Text] [Related]

  • 5. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.
    Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR, Louis DN, Bartus RT, Hochberg FH, Chiocca EA.
    Nat Med; 1999 Aug 15; 5(8):881-7. PubMed ID: 10426310
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
    Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA.
    Cancer Res; 2010 Jan 15; 70(2):598-608. PubMed ID: 20068158
    [Abstract] [Full Text] [Related]

  • 11. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y, Todo T.
    Brain Nerve; 2009 Jul 15; 61(7):815-22. PubMed ID: 19618859
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1546-57. PubMed ID: 17077357
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Brain tumor therapy using replication--competent virus vectors].
    Todo T.
    Nihon Rinsho; 2005 Sep 01; 63 Suppl 9():504-9. PubMed ID: 16201572
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Varicella zoster virus infection of malignant glioma cell cultures: a new candidate for oncolytic virotherapy?
    Leske H, Haase R, Restle F, Schichor C, Albrecht V, Vizoso Pinto MG, Tonn JC, Baiker A, Thon N.
    Anticancer Res; 2012 Apr 01; 32(4):1137-44. PubMed ID: 22493342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.